Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6403MR)

This product GTTS-WQ6403MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6403MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6113MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ232MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ5507MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ11345MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ7015MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ386MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ6129MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ247MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW